The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: A UK/Ireland and European benchmarking comparative analysis

Bone Marrow Transplantation

Volumn 46, Issue 9, 2011, Pages 1210-1218

  Cook, G ^a   Jackson, G H ^b   Morgan, G J ^c   Russell, N ^d   Kirkland, K ^e   Lee, J ^e   Pearce, R ^e   Marks, D I ^f   Pagliuca, A ^g  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e GUY S HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

autograft; benchmarking; myeloma; OS

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; EUROPE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; SALVAGE THERAPY; UNITED KINGDOM;

ADULT; AGED; COMBINED MODALITY THERAPY; EUROPE; FEMALE; GREAT BRITAIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRELAND; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 80052452440     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.283     Document Type: Article

References (28)

1. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822-824. (Pubitemid 13013370)
2. Lazarus HM, Phillips GL, Herzig RH, Hurd DD, Wolff SN, Herzig GP. High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol 2008; 26: 2240-2243.
3. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006; 132: 410-451.
4. Blade J, Esteve J, Rives S, Martinez C, Rovira M, Urbano-Ispizua A et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26: 845-849.
5. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502. (Pubitemid 38010075)
6. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883. (Pubitemid 36532313)
7. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97. (Pubitemid 26240110)
8. Harousseau JL. Stem cell transplantation in multiple myeloma (0,1, or 2). Curr Opin Oncol 2005; 17: 93-98.
9. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11. (Pubitemid 30017218)
10. Blade J, San Miguel JF, Fontanillas M, Esteve J, Maldonado J, Alcala A et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J 2001; 2: 272-278. (Pubitemid 32771602)
11. Fermand JP, Brechignac S. The role of autologous stem cell transplantation in the management of multiple myeloma. Pathol Biol (Paris) 1999; 47: 199-202. (Pubitemid 29128443)
12. Russell NH, Szydlo R, McCann S, Potter MN, Craddock C, Towlson K et al. The use of a national transplant registry to benchmark transplant outcome for patients undergoing autologous and allogeneic stem cell transplantation in the United Kingdom and Ireland. Br J Haematol 2004; 124: 499-503. (Pubitemid 38230596)
13. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123. (Pubitemid 28435189)
14. Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152-1157.
15. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
16. Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93: 345-351. (Pubitemid 26148738)
17. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
18. Cheema PK, Zadeh S, Kukreti V, Reece D, Chen C, Trudel S et al. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transplant. Biol Blood Marrow Transplant 2009; 15: 686-693.
19. Bensinger WI. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 2009; 23: 442-448.
20. Louw VJ, Louw H, Webb MJ. Autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2009; 361: 1118-1119; author reply 1119.
21. Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman SR et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007; 25: 4933-4937. (Pubitemid 350220425)
22. Zee B, Cole B, Li T, Browman G, James K, Johnston D et al. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol 1998; 16: 2834-2839. (Pubitemid 28363049)
23. Harousseau JL. Induction therapy in multiple myeloma. Hematology Am Soc Hematol Educ Program 2008, 306-312.
24. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498-1505. (Pubitemid 44736116)
25. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008; 93: 124-127. (Pubitemid 351156161)
26. Rosinol L, Oriol A, Mateos MV, Sureda A, Garcia-Sanchez P, Gutierrez N et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007; 25: 4452-4458. (Pubitemid 350013852)
27. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473. (Pubitemid 44264086)
28. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008; 22: 231-239. (Pubitemid 351250526)